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Abstract. Dried blood spot (DBS) sample collection has gained increased interest across the
pharmaceutical industry as a potential alternative to plasma for pharmacokinetic (PK) evaluations.
However, regulatory guidelines and examples of late-stage clinical trial applications in the literature are
lacking. This paper communicates Merck’s strategy for the implementation of DBS exempliﬁed by
experience on a late-stage program (MK-8931). In this program, DBS was proposed as the sole matrix for
phase 3 studies to decrease logistical burden in an aging target patient population (Alzheimer’s disease).
In vitro and bioanalytical tests demonstrated initial method feasibility and suitability for further
evaluations in the clinic. An in vivo dataset was developed initially in healthy subjects (phase 1 study)
and then in patients (phase 2/3 study) to establish a quantitative relationship between the blood and
plasma concentrations (bridging dataset) using descriptive and population PK analyses. This allowed for
PK conclusions to be seamlessly drawn across the clinical program without impact from the choice of
matrix. This integrated information package (in vitro, bioanalytical and clinical) was presented to major
regulatory agencies (FDA and EMA) for regulatory input. Based on this package, regulatory
concurrence was gained on accepting DBS as the sole matrix in late-stage clinical trials.
KEY WORDS: bridging; dried blood spots; MK-8931; population PK.
INTRODUCTION
Since its original application for the detection of
phenylketonuria in neonates half a century ago, dried blood
spots (DBS) have gained popularity as a screening tool for
various diagnostic tests including metabolic disorders, thera-
peutic drug monitoring, and HIV infection in neonates (1–3).
The pharmaceutical industry and regulators have continued
to explore the potential of DBS as a viable alternate matrix
for pharmacokinetic analyses (4–6). DBS was initially evalu-
ated at Merck in 2001 for discovery stage PK studies and
subsequently implemented for the pediatric development
program of an anti-HIV compound in 2009. Since then, a
number of compounds have been evaluated for initial in vitro
and bioanalytical feasibility to implement DBS. A subset of
these has progressed to implementation of DBS in clinical
trials, including late-stage clinical trials. Strategically, Merck
has chosen to primarily focus the application of DBS towards
late-stage patient studies (phase 2 and/or 3) where it has the
potential to render greater impact. In our opinion, the value
proposition for DBS from a clinical perspective is as follows:
(a) To add ﬂexibility in the collection of PK data in
phases 2 and 3 studies: Typically, sparse PK samples
in phases 2 and 3 studies are constrained to limited
time windows during a clinic visit. DBS, particularly
in an out-patient setting, expands the window for
access to such data. This may be especially beneﬁcial
for drugs with long half-lives or long acting formu-
lations to evaluate steady-state or time for washout,
or where clinical endpoints are collected by patient-
completed diaries or are episodic (e.g., migraine,
asthma, or erectile dysfunction trials). However,
sampling methods in an out-patient setting need to
mature further to gain adequate precision for
pharmacokinetic modeling.
(b) Decreased patient burden (blood volume) in vulner-
able populations: The smaller sample volumes typi-
cally associated with DBS (three spots of ∼20–40 μL
each) vs. typical plasma samples (∼200–1000 μL) are
clinically attractive for vulnerable populations where
blood volumes are a clinical or ethical concern (e.g.,
younger pediatric or elderly populations). However,
DBS should not be considered an automatic choice
for studies in such populations. Equal consideration
should be given to liquid microsampling approaches.
(c) Improved logistical feasibility: DBS sampling offers a
number of logistical advantages (e.g., ambient tem-
perature storage or shipping, no need for specialized
equipment such as refrigerated centrifuges and
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simpliﬁed sample preparation) that may reduce
operational burden associated with PK sampling in
larger multi-center patient trials and lead to potential
cost savings. A reduced operational burden may
encourage greater participation of clinical sites for
PK evaluation in phases 2 or 3 trials, and thereby
enrich the database for characterization of the
population pharmacokinetics and exposure-response
relationships. Prior to implementing ambient ship-
ping for DBS, the extended stability of DBS samples
should be established to ensure integrity of the
samples.
DBS has been used extensively for the measurement of
endogenous biomarkers of disease (7,8). Merck is exploring
the use of DBS for clinical laboratory tests and biomarkers.
Continued development of these approaches and coordina-
tion with PK measurements is anticipated to further enhance
the value proposition for DBS in clinical trials.
Despite the upside potential of DBS, companies and
regulators have wrestled with its utility and regulatory
expectations compared to traditional matrices. Recently, the
European Bioanalysis Forum (EBF) and IQ have published
position papers reﬂecting a range of opinions on DBS (9,10).
However, industry regulatory consensus positions and regu-
latory guidelines for DBS in clinical development programs
have been slow to emerge. Further, with few exceptions, the
literature has focused on technological challenges and
bioanalytical considerations. Rowland and Shepard provide
an overview of the requirements for the interpretation of
DBS data in development and addressed some of the
regulatory considerations that would pave the way to gaining
acceptance for DBS (11). A theoretical assessment of
pharmacokinetic considerations in the interpretation of DBS
data has been published by Emmons and Rowland (12).
However, the literature lacks in-depth guidance on pharma-
cokinetic analyses, modeling, or late-stage clinical consider-
ations, especially when integrating across a clinical program
with studies that include both plasma and DBS sampling.
The use of DBS should be thoughtfully weighed on a
case-by-case basis with consideration to pros/cons of its use
relative to traditional matrices for a given program. Success-
ful implementation hinges on prospective multi-disciplinary
(e.g., Bioanalytical, pharmacokinetic-pharmacodynamic
(PKPD), Clinical Pharmacology, regulatory) planning. As
most clinical development programs employ plasma sampling
for phase 1 studies, a robust in vivo bridging strategy should
be developed that allows quantitative inter-conversion of
pharmacokinetic information between matrices. This allows
pharmacokinetic conclusions to be drawn across studies
agnostic to matrix. The overarching PKPD objectives for
the program (e.g., evaluation of intrinsic/extrinsic factors,
exposure-response) should remain a core consideration and
not be impacted by the choice of the bioanalytical matrix.
This paper presents Merck’s strategy for the application
of DBS in clinical programs which has been shaped by
experience gained from implementation on clinical programs.
This augments an earlier company position paper where
initial experience, bioanalytical, and logistical considerations
were communicated (6). Of note, this summary is intended to
inform the scientiﬁc community of an emerging area of
interest with limited industry or regulatory precedence and
is not intended to represent a broader consensus position by
regulators or industry. The strategy is composed of staged
implementation steps where initial methodological feasibility
is established through a series of in vitro and bioanalytical
evaluations. DBS is introduced in a staged manner in the
clinic whereby DBS samples are taken concurrently with
plasma initially in a healthy subject study and then in patients.
Descriptive and population PK analyses of these data are
conducted in a Blearn and conﬁrm^ paradigm. Regulatory
feedback is sought on this comprehensive data package
(Fig. 1). Implementation of this strategy is exempliﬁed
through experience gained from MK-8931, a clinical program
where regulatory concurrence was gained for the acceptance
of DBS as the sole PK collection matrix for late phase trials.
CASE STUDY: MK-8931
Strategic Rationale. MK-8931 is currently in late-stage devel-
opment for Alzheimer’s disease. DBS would allow for
shipping at ambient temperature and render a number of
other logistical advantages that could encourage clinical site
participation and facilitate faster study enrollment for large
multi-site clinical trials. Additionally, the reduced blood
volume associated with DBS collection was anticipated to
reduce patient burden. The goal of implementation was to
pursue DBS as the sole matrix for late-stage clinical trials.
The characterization of exposure-response relationships was
considered an important element for dose justiﬁcation. Thus,
the bridging package needed to be robust to allow clinical
studies to be pooled across the clinical program for popula-
tion PK and exposure-response analyses in anticipation of
regulatory submission and labeling.
Initial Feasibility Assessment
Initially, a set of in vitro and bioanalytical assessments were
conducted to ascertain methodological feasibility prior to further
evaluations in the clinic. These tests were conducted over a
clinically relevant concentration range and required good com-
munication between the bioanalytical and PKPD scientists.
In Vitro Tests. As detailed in the publication of Rowland and
Emmons (12), plasma protein binding, blood–cell to unbound
plasma concentration ratio (ρ), and hematocrit are important in
vitro determinants of the blood to plasma ratio and the suitability
of DBS as a pharmacokinetic matrix. Emmons and Rowland
hypothesize that compounds with a blood to plasma ratio ranging
from 0.55 to 2, and non-concentration-dependent unbound
fraction (fu) and ρ can be equally analyzed by blood or plasma
(5,12).
The average MK-8931 in vitro blood to plasma ratio
was 1.22 at 1 μM based on radiolabelled experiments. The
blood to plasma ratio was concentration independent in the
range of 0.03 to 10 μM (bracketing the clinical concentra-
tion range). MK-8931 was modestly plasma protein bound
(~65% in human plasma) and not concentration dependent
in the range of 0.03 to 1 μm. The in vitro tests showed that
DBS or plasma would be equally valid as a matrix for MK-
8931 PK assessments.
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Bioanalytical Tests. Prior disseminations summarize Merck’s
strategy for evaluating bioanalytical feasibility (6,13). These
tests encompass assay sensitivity and range, DBS card type
and extraction methods, the impact of hematocrit on the
bioanalytical method over a wide range, impact of spot
volume/homogeneity, stability (including relevant metabo-
lites) at extremes of temperate and relative humidity (poten-
tially encountered during shipping), and any considerations
speciﬁc to the quantitation of the molecule (e.g.,
concentration-dependent binding to target and/or plasma).
There are currently no established regulatory guidances for
bioanalytical method development or validation speciﬁc to
DBS. Hence, following a decision to pursue DBS, regulatory
bioanalytical guidelines, internal SOPs, and industry best
practices for plasma assays are applied for bioanalytical
validation.
For MK-8931, venous blood was drawn into a single
EDTA collection vial and a small quantity spotted onto
a DBS card; the remaining blood sample was centri-
fuged to extract plasma. MK-8931 concentrations were
analyzed in both the DBS and the plasma samples. The
DBS analytical method was based on either direct
extraction or direct extraction followed by liquid–liquid
extraction of MK-8931 from human dried blood spots
on DMPK-A cards. The analyte from DBS samples and
its stable isotope labeled internal standard contained in
the extraction solvent were analyzed by HPLC-MS/MS.
The lower limit of quantitation (LLOQ) was 1 ng/mL
with a 3-mm punch size and was deemed adequate for
clinical trials. Hematocrit was shown not to have an
analytically relevant effect on MK-8931 concentration
measurements in the range of 19.5 to 86.0%. Following
the receipt of clinical study samples, incurred sample re-
analysis (ISR) was completed to further validate the
reproducibility of the assay methodology. Assay valida-
tion and clinical performance are summarized in
Tables I and II. Bland-Altman plots comparing DBS
and plasma concentrations showed a lack of bias
between the methods (Fig. 2). The DBS analytical
method was considered to have robust performance for
use in a clinical setting.
In other instances, bioanalytical evaluations have ruled
out DBS as a possible matrix. For example, one compound
exhibited high levels of a circulating glucuronide metabolite
and stability testing of DBS samples containing the
glucuronide showed that it back-converted to parent
compound at both room temperature and low temperature
with acidiﬁcation. This would confound the accurate
measurement of the parent compound. Therefore, traditional
plasma sampling with acidiﬁcation to stabilize the metab-
olite was considered a more viable option, and DBS was not
further pursued. In other instances, DBS has been success-
fully evaluated in early clinical studies, but the program




As most clinical development programs are initiated
with, and likely to retain phase 1 studies with plasma assays, a
quantitative in vivo relationship between blood and plasma
concentrations is established through Bbridging studies.^
These typically encompass a staged evaluation commencing
in a healthy subject study and then proceeding to a patient
study. In each study, DBS and plasma samples are taken
concurrently at various PK sampling time points that span a
therapeutically relevant concentration range. Depending on
whether the proposed future clinical trial (after bridging is
established) would continue blood collection through veni-
puncture or in an out-patient setting, DBS may be collected
via venipuncture in the clinic or through ﬁnger sticks. As
sample collection has a direct impact on the quality of DBS
assessments, Merck has developed extensive training material
Fig. 1. Components of the integrated DBS strategy
Table I. Assay Validation Performance Summary for MK-8931




Regression model analysis Replicate standard curves
(linear, 1 / x2)
5 92.0–105 3.7–7.3
Intra-run accuracy and precision at the LLOQ 3 core runs 5 in each run 101–111 9.2–18.9
Intra-run accuracy and precision at low, mid,
and high QC
3 core runs 5 in each run 99.4–109 2.4–7.3
Inter-run accuracy and precision at LLOQ,
low, mid, and high QC
Mean of 3 core runs in 3 days 3 101–107 0.8–4.9
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(including videos and educational materials) for sites for
guidance on sample handling, and shipping. The participation
of PKPD and/or BA scientists in start-up meetings is encour-
aged to ensure participating sites are appropriately educated on
practical considerations of sample collection and handling.
For the healthy subject evaluation, an existing clinical
pharmacology study (e.g., multiple ascending dose, control
arm of a DDI, or special population study) should be
leveraged. No a priori sample size is recommended; a
typically sized clinical pharmacology study (e.g., 12–16
subjects) is sufﬁcient. Subsequently, bridging data should be
collected from an early patient study (e.g., phase 1b or POC).
Merck utilizes a Bweight of evidence^ approach that
includes a series of graphical/descriptive evaluations and with
equal or greater weightage given to population pharmacoki-
netic analyses. These analyses should follow a learn and
conﬁrm paradigm. Analyses should commence with the
healthy subject study in an exploratory or Blearning^ mode
and be conﬁrmed in the patient study. Based on input
provided for MK-8931 during the EMA oral hearing, an
external qualiﬁcation of the blood–plasma relationship is
highly desirable. Establishing and qualifying this relationship
enables pharmacometric analyses of concentration data
across studies in a clinical program in support of the
submission package and labeling.
Healthy Study
For MK-8931, DBS was initially included along with
plasma concentrations in healthy subjects in a clinical
pharmacology study (12 subjects contributing 11 samples
each). DBS samples were collected via venipuncture in the
clinic. A number of graphical and descriptive analyses were
conducted. Concurrently drawn DBS and plasma concentra-
tions were plotted to explore data trends (Fig. 3a). The blood
to plasma slope (95% CI) estimated by regression was 1.29
(1.27, 1.31), which was in close agreement with the in vitro
estimated blood to plasma (B:P) ratio of 1.22. Of note, while
regression ﬁts may be applied to quantify the relationship, a
prospective R2 cutoff should not be applied as a go/no go
criterion. Further, non-linear trends should not be inferred as
a lack of utility of DBS. Observed mean (Fig. 3b) and
individual (Fig. 3c) concentrations were plotted by nominal
time. The plots include MK-8931 concentration data derived
from plasma, DBS, and BDBS-predicted plasma
concentrations^ (DBS concentration divided by the slope
from regression ﬁt of 1.29). The measured and DBS
converted plasma concentrations were generally comparable
and followed similar trends over time. These graphical and
descriptive analyses suggested that the in vivo B:P relation-
ship was well characterized in healthy subjects.
In Merck’s experience, the aforementioned graphical
plots have been well received by regulators. Additionally, a
mixed-effects modeling approach could be applied to evalu-
ate the blood and plasma concentration data. In this
approach, time-matched DBS and plasma concentration data
pairs are ﬁ t ted to a mixed-effects model (e.g . ,
ln(DBS) = slope * ln (plasma)) in a program such as
NONMEM. Inter- and intra-individual variability terms as
well as the inﬂuence of covariates such as hematocrit may be
evaluated using this approach.
Equal or greater weightage was applied to population
PK as a critical element of the overall bridging strategy.
Implementation followed a learn and conﬁrm paradigm as
shown in Fig. 4. MK-8931, DBS, and plasma concentration
data from the phase 1 study were used to update an
existing plasma population pharmacokinetic model. Blood
concentrations were modeled as a separate compartment
with an estimated population Bslope^ that related blood
and plasma concentrations (Fig. 5). Separate residual
error terms were applied for blood and plasma. Parameter
estimates and errors were similar between a model that
included plasma data alone and one that included plasma
and DBS and were consistent with historical knowledge of
the compound (Table III). The population slope (%
relative standard error) estimated from the model was
1.27 (4.61%) and similar to that obtained from the
regression analyses and the in vitro blood to plasma ratio.
Table II. Assay Clinical Study Performance Summary for MK-8931
Clinical Protocol
Mean Accuracy (%) Mean Precision (Coefﬁcient of Variation %)
N QC L QC M QC H N QC L QC M QC H
PN0A 6 93.7 103 95.9 6 14.6 5.80 3.84
PN0B 40 99.9 102 101 40 8.44 2.87 5.21
Fig. 2. Bland–Altman plot comparing plasma and DBS concentrations
for pharmacokinetic samples from the phase 1 study for MK-8931
Fig. 3. a Correlation of blood and plasma concentration data from a
phase 1 bridging study of MK-8931. b Mean plasma and blood
concentration-time data from a phase 1 bridging study of MK-8931.
Note: DBS-predicted plasma concentrations were calculated as
measured DBS divided by 1.29, the slope of the DBS-plasma linear
regression line. c Plasma and blood concentration-time data for
individual subjects from a phase 1 bridging study of MK-8931. DBS-
predicted plasma concentrations were calculated as measured DBS
divided by 1.29, the slope of the DBS-plasma linear regression line
b
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The impact of inter-individual variability on slope was
explored and found not to be signiﬁcant. Existing covar-
iate relationships from the plasma model were applied to
the plasma-DBS model; however, the impact of covariates
on the slope was not evaluated at this stage. Random
effects and residual errors for the parameters were within
reasonable limits. Other key modeling parameters (e.g.,
clearance) were also well estimated which would be of
relevance to support covariate analyses (a key objective
for the phase 2/3 population PK evaluations).
Modeling best practices and diagnostics were applied to
explore the goodness of ﬁt and the quantitative interchange-
ability of exposure metrics derived from the two matrices.
Standard diagnostics and goodness of the ﬁt plots such as visual
predictive checks or CWRES (conditional weighted residuals)
or IWRES (individual weighted residuals) vs. time plots
differentiated by matrix were used to rule out the patterns of
systematic bias or model mis-speciﬁcation. Another useful
diagnostic was to compare the individual post hoc plasma
exposures from the plasma-DBS bridging study using (1) the
plasma data from the bridging study and the plasma alone
model and (2) the DBS data from the bridging study and the
plasma+DBSmodel, using model-estimated slope to convert to
a plasma exposure. DBS-based exposure estimates were similar
and did not show any over- or under-prediction bias compared
to the plasma-based estimates (Fig. 6).
Of note, while the blood to plasma relationship of MK-
8931 was linear, if the underlying relationship for a given
compound is non-linear, a more complex parametric descrip-
tion could be developed. However, the increased
parameterization would need to be balanced relative to the
overall advantages conferred by DBS to the program.
Patient Study
Descriptive and population analyses in healthy subjects
supported the continued utility of DBS. Therefore a subse-
quent bridging dataset was developed in patients to conﬁrm
this relationship in a more heterogeneous and relevant
patient population. For MK-8931, this was obtained from an
early cohort of patients in a late-phase clinical trial. Concur-
rent DBS and plasma samples by venipuncture in clinic were
taken pre-dose and as three sparse PK samples over a 13-
week period. Additional DBS and plasma samples continued
to be collected from the study based on advice received at an
EMA oral hearing to develop an external qualiﬁcation
dataset.
Simulations using the phase 1 pop PK model were used to
develop prospective go/no go decision criteria and included in
the modeling analysis the plan for the patient study to support
the decision of whether DBS could be used as the solematrix for
future phase 3 studies. The modeling analysis plan would
evaluate (i) comparability of model-estimated slope to regres-
sion estimated (in vivo) and in vitro blood to plasma ratio, (ii)
similarity and lack of bias in parameters and post hoc exposures
derived from plasma and DBS converted to plasma, and (iii)
similar central tendency of plasma predicted vs.DBS converted
plasma predicted exposures. For MK-8931, two decision trees
were included in the modeling analysis plan (Fig. 7). These
decision trees represent program-speciﬁc criteria and need to be
adjusted on a case-by-case basis. Based on discussions at the
EMAoral hearing, themodeling plan was updated to include an
external qualiﬁcation step where the DBS-plasma population
PK model (including the population slope term) would also be
used to estimate exposures (based on DBS data alone) for an
additional set of patients not utilized for the model
development.
A similar set of descriptive and graphical analyses as
those performed on data from healthy subjects was planned
for data from the patients. Furthermore, the population PK
model would be updated with patient-derived DBS data and
assessed relative to the proposed modeling plan and decision
trees. Additional patient data from this data, not included in
model development, would be used for external qualiﬁcation.
In its totality, the modeling plan was designed to evaluate
whether DBS could achieve the broader PK objectives of the
clinical program, such as application for exposure-response
modeling, with a similar degree of ﬁdelity as plasma. These
pharmacometric assessments (as well as the preceding
strategic, in vitro and bioanalytical components) were a
critical aspect of the package submitted to regulatory agencies
for feedback on whether DBS would be suitable as the sole
matrix for late-stage studies. For blinding considerations,
results from the patient study are not included in the current
dissemination. These will be the subject of a subsequent
external communication upon unblinding of the study.
Regulatory Input
As clinical application of DBS is still emerging,
regulatory guidance on DBS is yet to be established. Thus,
Fig. 4. Road map for application of population PK to establish a
quantitative bridge between plasma and DBS concentrations
Fig. 5. A base population pharmacokinetic model structure that
relates plasma and DBS concentration data by a population estimated
slope. See Appendix for example NONMEM code
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feedback from key regulatory agencies is recommended in
a timely manner for each program. The brieﬁng package
should present an integrated assessment of in vitro data,
bioanalytical feasibility assessments, and in vivo bridging
evaluations. The timing of such correspondence is program
speciﬁc and should enable subsequent ﬁnalization of late-
stage clinical plans. We recommend that meeting requests
specify input from pharmacometric and bioanalytical re-
viewers. The inclusion of external expert opinions as part
of the submitted dossier may be considered. It is Merck’s
experience that comprehensive data packages that included
the elements mentioned above enabled more productive
regulatory interactions.
This approach was used for MK-8931. The focus of the
interactions was to gain regulatory concurrence that the
submitted package supported the use of DBS (collected in
the clinic via venipuncture) as the sole method of PK
sampling in ongoing and future MK-8931 late-stage clinical
trials. For MK-8931, FDA interactions occurred at an earlier
time frame when the DBS-associated pharmacometric
package was not as well developed. The submitted package
primarily relied on in vitro and BA feasibility assessments and
descriptive/graphical analyses of phase 1 clinical data along
with plans for the collection of plasma and DBS bridging data
in patients, and the agency agreed that our proposal appeared
reasonable. During correspondence, the agency recom-
mended the use of the individual concentration time proﬁles
as denoted in Fig. 3c. A comprehensive background docu-
ment (inclusive of pharmacometric evaluations) was submit-
ted for scientiﬁc advice to the CHMP/EMA. The agency
requested an oral hearing as they indicated that this was their
ﬁrst regulatory experience of DBS. The key input received
were the following:
& Merck has presented a comprehensive approach
consisting of bioanalytical feasibility considerations
and in vitro studies followed by an in vivo bridging
program in both healthy and patient populations.
Overall, this approach was considered robust to
support the use of DBS as the sole source of PK
Table III. Phase 1 MK-8931 Population PK Model Parameter Estimates (% Residual Standard Error) for Relevant Parameters
Parameter Parameter Description
Plasma-Only Modela Plasma +DBS Modelb
Estimate (%RSE) Estimate (%RSE)
Slope DBS/plasma ratio – 1.27 (4.61)
σ2plasma Additive residual variability for plasma 0.142 (7) 0.144 (7.29)
σ2DBS Additive residual variability for DBS – 0.186 (34.7)
aModel developed using phase 1 plasma data
bModel developed using Phase 1 plasma data as well as DBS data from a healthy volunteer bridging study
Fig. 6. Individual MK-8931 model-predicted exposures using plasma alone data and model vs. from DBS concentration data
converted to plasma using the model-estimated population slope
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data for the remainder of the MK-8931 phase 3
program.
& While the broader strategy was endorsed, the agency
cautioned that the implementation of DBS requires
unique considerations which may not be readily
translatable to other development programs.
& There was a strong focus on trying to understand the
impact of inter-individual variability on the slope and
to ensure that the blood to plasma relationship (i.e.,
slope) could be applied to describe populations not
included in the modeling dataset. The agency recom-
mended that external qualiﬁcation of the slope be
demonstrated to show its predictive value in a dataset
not used for model development.
& Of note, while the agency acknowledged the
potential future beneﬁts of home sampling, they
refrained from providing commentary as they
considered it to be technology in the early stages
of development.
As stated before, the dissemination of this regulatory
interaction is intended to advance the ﬁeld by sharing
knowledge in an area with relatively little regulatory
precedence or guidance and as such is not intended to
reﬂect a broader regulatory position statement.
DISCUSSION
The strategy for using DBS in clinical programs at
Merck has been developed over several years and has
been a non-linear process. Merck arrived at its current
state by looking at DBS holistically in the context of
individual development programs, avoiding a one-size-ﬁts-
all approach. Early efforts mainly focused on analytical
aspects, and it was only after a whole program approach
was adopted, which the broader utility of DBS has started
to be realized. Merck’s strategy requires a prospective and
multi-study approach to build the data sets to enable
successful clinical implementation. As such, the alignment
of all groups (analytical, pharmacokinetics, clinical, oper-
ations) involved is critical to the successful implementa-
tion of DBS. The input from regulatory agencies has been
critical to the reﬁnement of our strategy. The feedback on
Fig. 7. a MK-8931 DBS-plasma decision tree no. 1 (linear regression analysis based on
patient data only). b MK-8931 DBS-plasma decision tree no. 2 (population PK model-
based analysis based on healthy volunteer and patient data)
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both the analytical and pharmacokinetic aspects demon-
strated scientiﬁc insightfulness and curiosity, while em-
bracing a forward-looking attitude. As with any new
approach, Merck anticipates unexpected hurdles during
the development and implementation stages. Learning
from the large-scale implementation of DBS in these trials
is likely to beneﬁt the broader community and will be the
subject of future disseminations.
Future Perspective
Merck believes that the strategies described above will
help transform DBS from a niche bioanalytical technology to
a practical clinical strategy that can be leveraged for
population-based PKPD models suitable for regulatory
submissions. Presentations of such data packages to regula-
tors should build regulatory conﬁdence in acceptance of DBS
as a mainstream matrix and presumably inﬂuence future
regulatory guidance. Merck believes that investing in novel
methodologies such as these is an essential part of the
solution to addressing rising drug development costs, while
still meeting regulatory agencies expectations to demonstrate
a robust understanding of the PKPD relationship of new
therapeutic agents and demands by payers to reduce costs.
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APPENDIX
Population Analyses of DBS and Plasma Concentration
Data: Excerpt from NONMEM Code within $ERROR Block
Q1= 0




IF (CPT.EQ.3 .AND. F.GT.0) Q2= 1
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